Cargando…

Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4(+)CD25(+)Foxp3(+ )regulatory T cells in COPD

BACKGROUND: Salmeterol and fluticasone combination (SFC) has anti-inflammatory effects and improves clinical symptoms in patients with chronic obstructive pulmonary disease (COPD). However, the anti-inflammatory mechanism of SFC remains unclear. In this study, we investigated the inflammatory respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Li, Ma, Qian-li, Yao, Wei, Zhang, Qiao, Chen, Hua-ping, Wang, Guan-song, Wang, Chang-zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234191/ https://www.ncbi.nlm.nih.gov/pubmed/22032685 http://dx.doi.org/10.1186/1465-9921-12-142

Ejemplares similares

Salmeterol/fluticasone combination in the treatment of COPD
por: Chung, K F
Publicado: (2006)

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
por: Balint, Beatrix, et al.
Publicado: (2010)

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
por: Yawn, Barbara P, et al.
Publicado: (2010)

Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
por: Singh, Dave, et al.
Publicado: (2014)

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD
por: Gao, Jinming, et al.
Publicado: (2015)

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
por: Singh, Dave, et al.
Publicado: (2015)

Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
por: Dalal, Anand A, et al.
Publicado: (2010)

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
por: Zhong, Nanshan, et al.
Publicado: (2015)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017)

Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD)
por: Mills, Hilla, et al.
Publicado: (2022)

Age-related changes in CD4(+)CD25(+)FOXP3(+) regulatory T cells and their relationship with lung cancer
por: Hou, Pan-Fei, et al.
Publicado: (2017)

Ipratropium bromide is more effective than Salmeterol — Fluticason combination on O(2) saturation patients with COPD
por: Rezaie, Nader, et al.
Publicado: (2013)

Evaluation of Fluticasone Propionate and Fluticasone Propionate/Salmeterol Combination on Exercise in Pediatric and Adolescent Patients with Asthma
por: Murray, John J, et al.
Publicado: (2011)

The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age
por: Yoshihara, Shigemi, et al.
Publicado: (2019)

The control of CD4(+)CD25(+)Foxp3(+ )regulatory T cell survival
por: Pandiyan, Pushpa, et al.
Publicado: (2008)

Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
por: Tamura, Tomohiro, et al.
Publicado: (2016)

Pharmacokinetic characteristics of fluticasone, salmeterol and tiotropium after concurrent inhalation
por: Sunwoo, Jung, et al.
Publicado: (2017)

Androgen receptor modulates Foxp3 expression in CD4(+)CD25(+)Foxp3(+) regulatory T-cells
por: Walecki, Magdalena, et al.
Publicado: (2015)

The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis
por: Guan, Renzheng, et al.
Publicado: (2019)

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
por: Bjermer, Leif, et al.
Publicado: (2017)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
por: Anzueto, Antonio R., et al.
Publicado: (2018)

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD
por: Herth, Felix, et al.
Publicado: (2020)

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma
por: Houghton, Catherine M, et al.
Publicado: (2007)

Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease
por: Koser, Andras, et al.
Publicado: (2010)

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
por: Jin, Xiaofen, et al.
Publicado: (2020)

Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone
por: Teply, Robyn, et al.
Publicado: (2010)

Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma
por: Bullone, Michela, et al.
Publicado: (2017)

Dexamethasone/salmeterol/fluticasone-propionate: Invasive pulmonary Aspergillosis: case report
Publicado: (2021)

Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies
por: Siler, Thomas M., et al.
Publicado: (2016)

Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
por: Moretz, Chad, et al.
Publicado: (2020)

Effectiveness and Treatment Compliance of Salmeterol–Fluticasone Easyhaler(®) Among Patients with Asthma, COPD, or Asthma–COPD Overlap Syndrome: Real-World Study Findings
por: Tamási, Lilla, et al.
Publicado: (2022)

CD4(+)CD25(high)FoxP3(+) Regulatory T-cells in Hematologic Diseases
por: Moon, Hee-Won, et al.
Publicado: (2011)

Conversion of Peripheral CD4(+)CD25(−) Naive T Cells to CD4(+)CD25(+) Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3
por: Chen, WanJun, et al.
Publicado: (2003)

CD4(+)CD25(+)FOXP3(+) Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer
por: Clarke, Sarah L., et al.
Publicado: (2006)

Are CD4(+)CD25(-)Foxp3(+ )cells in untreated new-onset lupus patients regulatory T cells?
por: Yang, Hua-xia, et al.
Publicado: (2009)

Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization
por: Ainali, Nina Maria, et al.
Publicado: (2020)

Effect of salmeterol/fluticasone combination on the dynamic changes of lung mechanics in mechanically ventilated COPD patients: a prospective pilot study
por: Chen, Wei-Chih, et al.
Publicado: (2016)

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
por: Vogelmeier, Claus, et al.
Publicado: (2016)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
por: Wedzicha, Jadwiga A, et al.
Publicado: (2017)

The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device
por: Tashkin, Donald P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9kff6fgj01bpk9rf0jchv8l992